[LETTERHEAD OF MOLECULAR DIAGNOSTICS]                              PRESS RELEASE
                                                           For immediate release


CONTACTS:

Molecular Diagnostics, Inc.
---------------------------
Denis M. O'Donnell, M.D.
Chief Executive Officer
(312) 222-9550

                      MOLECULAR DIAGNOSTICS, INC. ANNOUCES
                              DIRECTOR RESIGNATION

CHICAGO, IL, March 8, 2005 - Molecular Diagnostics, Inc. (OTCBB: MCDG.OB)
announced today that Peter Gombrich, Chairman of the Board of Directors,
resigned as Chairman of the Board and as a director of the company, effective
today.

About Molecular Diagnostics, Inc.
Molecular Diagnostics develops cost-effective cancer screening systems, which
can be utilized in a laboratory or at the point-of-care, to assist in the early
detection of cervical, gastrointestinal, and other cancers. The InPath(TM)
System is being developed to provide medical practitioners with a highly
accurate, low-cost, cervical cancer screening system that can be integrated into
existing medical models or at the point-of-care.

More information is available at: www.Molecular-Dx.com

Certain statements in this release are forward-looking. These statements are
based on Molecular Diagnostics' current expectations and involve many risks and
uncertainties, such as the company's inability to obtain sufficient financing,
the possibility that clinical trials will not substantiate Molecular
Diagnostics' expectations with respect to the InPath(TM) System, and other
factors set forth in reports and documents filed by Molecular Diagnostics with
the Securities and Exchange Commission. Actual results may differ materially
from Molecular Diagnostic's current expectations depending upon a number of
factors affecting the Company's business. These factors include, among others,
risks and uncertainties detailed in the Company's periodic public filings with
the Securities and Exchange Commission, including but not limited to the
Company's Annual Report on Form 10-K for the year ended December 31, 2003 and
its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2004, June
30, 2004 and September 30, 2004 (as amended). Except as expressly required by
law, Molecular Diagnostics undertakes no obligation to publicly update or revise
any forward-looking statements contained herein.